Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106


Cetuximab Inhibits Gastric Cancer Growth in vivo, Independent of KRAS Status

Author(s): Min Shi, Hailong Shi, Jun Ji, Qu Cai, Xuehua Chen, Yingyan Yu, Bingya Liu, Zhenggang Zhu and Jun Zhang

Affiliation: Departments of Surgery and Clinical Oncology, Shanghai Institute of Digestive Surgery, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, No. 197 Ruijin Er Road, Shanghai 200025, China


Mutation status of Kirsten rat sarcoma viral oncogene homolog (KRAS) may serve as a negative predictive marker of Cetuximab in treating colorectal cancer. The present study was to determine the role of KRAS status in EGFR antibody treatment for gastric cancer. KRAS status was clarified in SGC-7901 (wild type) and YCC-2 (G→A mutation) gastric cancer cell lines. Anti-proliferative and pro-apoptotic effects of Cetuximab were tested both in vitro and in vivo, the expression of phosphorylated (p) ERK, a downstream protein in EGFR-RAS-MEK pathway, was also analyzed. No significant in vitro anti-proliferative or pro-apoptotic effects of Cetuximab were observed in both cell lines. The growth of either SGC-7901 or YCC-2 gastric cancer xenograft was significantly inhibited by Cetuximab. Apoptosis was induced in SGC-7901 but not in YCC-2 xenografts after Cetuximab treatment. The expression of pERK was up-regulated in YCC-2 but not SGC-7901 xenografts after Cetuximab treatment. In conclusion, KRAS (G→A) mutation does not affect in vivo anti-cancer efficacy of Cetuximab.

Keywords: Cetuximab, gastric cancer, KRAS, pERK, proliferation

Rights & PermissionsPrintExport

Article Details

Page: [1 - 8]
Pages: 8
DOI: 10.2174/1568009614888140221100414